Our group first reported a linkage finding for bipolar (BP) disorder on chromosome 8q24 in a study of 50 multiplex pedigrees, with an HLOD score reaching 2.39. Recently, Cichon et al reported an LOD score of 3.62 in the same region using two-point parametric analysis. Subsequently, we published the results of a genome scan for linkage to BP disorder using a sample extended to 65 pedigrees in which chromosome 8q24 provided the best finding, an NPL score of 3.13, approaching the accepted score for suggestive linkage. We have now fine mapped this region of chromosome 8 in our 65 pedigrees by the addition of 19 microsatellite markers reaching a marker density of 0.8 cM and an information content of 0.84. After the addition of the new data, the original NPL score slightly increased to 3.25. Two-point parametric analysis using the model employed by Cichon et al obtained an LOD score of 3.32 for marker D8S256 at h ¼ 0.14 exceeding the proposed threshold for genomewide significance. After adjusting the parameters in accordance with the 'common disease-common variant' hypothesis, multipoint parametric analysis resulted in an HLOD of 2.49 (a ¼ 0.78) between D8S529 and D8S256, and defined a 1-LOD interval corresponding to a 2.3 Mb region. No allelic association with the disease was observed for our set of microsatellite markers. Biologically, plausible candidate genes in this region include thyroglobulin, KCNQ3 coding for a voltagegated potassium channel and the gene for brain adenyl-cyclase (ADCY8).
Introduction
Bipolar (BP) disorder is a severe psychiatric illness characterized by recurrent depressions and manias. It is a major public health problem affecting 1% of the population. 1 There is an established but unknown genetic component to BP disorder, [2] [3] [4] and it is likely that multiple genes contribute to disease susceptibility. 5, 6 There are now a number of regions (4p, 12q, 13q, 18q, 21q) that have been identified by linkage in independent studies. 7 Recently, a susceptibility locus on chromosome 8q24 was supported by two independent genomewide scans of BP disorder. Cichon et al 8 reported a peak LOD of 3.62 at D8S514 in 75 BP families using a dominant model in a parametric twopoint analysis, which overlaps with our previously reported finding on 8q24 using our initial 50 multiplex BP pedigrees. 9 In that study, the strongest finding was an HLOD of 2.39 (a ¼ 0.42) between D8S256 and D8S272, while other positive findings were on chromosomes 4 and 7. We have now extended our sample to 65 families, and in a recent genome scan 10 our best finding was an NPL of 3.13 (P ¼ 0.003) at D8S256 on 8q24. We report here the analysis of the fine mapping of this region in these 65 BP pedigrees. An additional 19 microsatellite markers were typed and analyzed using the dominant model described by Cichon et al. 8 The linkage evidence in the two-point analysis reaches genomewide significance and the multipoint analysis defines a region of 2.3 Mb likely to contain the susceptibility gene. Three candidate genes on 8q24 are briefly discussed.
Materials and methods
The sample and ascertainment criteria have been described elsewhere. 9, 10 Briefly, our ascertainment criteria required the proband to be a treated BPI patient, from a unilineal pedigree with at least two first-degree relatives affected with BPI, BPII, schizoaffective-manic (SAM) or recurrent unipolar disorder (RUP). All subjects were interviewed using the semistructured Schedule for Affective Disorders and SchizophreniaFLifetime version (SADS-L). 11 There were a total of 573 typed subjects for this study. We examined a narrow phenotypic model, where the 129 BPI, 97 BPII, and 7 SAM study subjects were considered affected, and a broad phenotypic model where the 69 RUP subjects were also considered affected. In both cases, the remaining relatives were coded as unknown.
Genotyping of the original marker-set has been described elsewhere. 9, 10 The additional markers were selected from the Marshfield database or the DeCode linkage map 12 and PCR conditions were retrieved from GDB. Alleles were separated by capillary electrophoresis of fluorescently labeled PCR products on an ABI-377 or an ABI-3700 genetic analyzer, multiplexing 8-10 products at a time. Allele sizes were determined using the Genescan and Genotyper software (Applied Biosystems) and binning was performed using internal software. Mendelian inconsistencies were detected using the Genetic Analysis System (GAS) version 2.0 (Alan Young, Oxford University 1993-95) and UNKNOWN. 13 All plates contained two or more DNA samples from the CEPH panel for quality control. Mendelian inconsistencies were checked through review of the original data and when they could not be resolved, the marker data for the family were deleted.
Marker HC83REP is a new polymorphic trinucleotide repeat that we identified starting at nucleotide 134 155 624 of the chromosome 8 sequence (UCSC golden path, November 2002 Freeze) within transcript AK023948. It was amplified using standard conditions and primers 5 0 -HEX-ACCCAGGGCTTCTCA-GACTT-3 0 and 5 0 -GAAACCTGGCACTCAGCTTC-3 0 at an annealing temperature of 551C. The Marshfield linkage map (http://research.marshfieldclinic.org/genetics/) was primarily used to determine recombination rates and marker order, while the DeCode map 12 and the UCSC (November 2002 Freeze) sequence were used for markers not present or not showing recombination to each other in the Marshfield database. When physical data were used, recombination fraction was approximated based on physical distances and recombination between flanking markers. There are no discrepancies between Marshfield, DeCode, and UCSC regarding marker order in our region of interest.
Nonparametric multipoint linkage analyses were performed with the GENEHUNTER-PLUS modification 14 of the GENEHUNTER package. 15 Parametric analyses were performed using the computer program FASTLINK V4.0 16 and LODSCORE from the LINK-AGE 5.10 program package. 13 Like Cichon et al, 8 we used a dominant model with a disease allele frequency of 0.009, a phenocopy rate (defined as the disease probability for those not carrying the disease allele) of 0.001 and a penetrance of 0.5. Parametric multipoint analysis was performed using GENEHUN-TER. The Cichon et al model provided much lower scores in multipoint than in two-point analyses. As multipoint analysis is much more sensitive to model misspecification, 17 we repeated the multipoint analysis using a set of parameters that better reflect the 'common disease-common variant' hypothesis 18 than the Cichon model. We assigned a lower penetrance (0.1) and a higher phenocopy rate (0.01) with a more frequent disease allele (P ¼ 0.06). The model was built based on a disease prevalence of 2%.
Family-based association analyses for the detection of excess transmission of specific alleles to affected individuals were performed using the computer program FBAT. 19 Results Figure 1 illustrates our nonparametric results, while Table 1 lists our nonparametric and two-point parametric results for both phenotypic models using the parameters of Cichon et al. 8 In the parametric analysis (narrow phenotypic model), eight markers exceeded the proposed threshold for suggestive linkage (1.9 for parametric analysis). The LOD score for D8S256 was 3.32, which exceeds the threshold for genomewide significance (3.3 for parametric analysis). 20 The results of the nonparametric analysis after the inclusion of the 19 additional markers were consistent with the results in the original marker set: An NPL of 3.25 (P ¼ 0.001), a marginal increase from the previous 3.13 (P ¼ 0.003).
Despite the strong two-point results, multipoint parametric analysis using the Cichon et al parameters in GENEHUNTER did not produce equally strong results (HLOD ¼ 1.22 at D8S256). It has been argued that model misspecification may have a serious impact on multipoint analysis, yet little impact on two-point analysis. 17 This prompted us to re-examine the Cichon et al 8 linkage parameters. A phenocopy rate of 0.001, when the prevalence is 0.01, implies that most cases are due to one gene. With a penetrance of 0.5, a carrier of the disease allele has a disease risk of 0.5 compared to a risk of 0.001 for a noncarrier, suggesting a very high genotype relative risk. This is in contrast to what the 'common disease-common variant' hypothesis 18 suggests. Using parameters consistent with such a hypothesis as described in our methods, we observed an HLOD of 2.49 (a ¼ 0.78) between markers D8S529 and D8S256. The results of the two-point and multipoint analysis using this model are summarized in Table 2 and Figure 2 . In 
Discussion
The present study substantially strengthens the evidence for a susceptibility locus on chromosome 8q24. We have added 19 markers on 8q24 increasing the marker density to 0.8 cM around 8q24. When using parametric analysis and the same model that gave the strongest signal in the study of Cichon et al, 8 we detected linkage evidence reaching genomewide significance. Our highest score is with D8S256, a marker located 18 cM (10.7 Mb) telomeric to their peak marker D8S514. Our finding maximizes at W ¼ 0.14 and the finding of Cichon et al maximizes at W ¼ 0.05. These recombination fractions may reflect the effects of intra-and inter-familial heterogeneity and the differences in informativeness of specific families. Precise localization awaits further analysis.
Of the markers reported in Cichon et al, 8 we have data for only one locus, D8S284 (see Table 1 ) for which they report a two-point LOD score of 1.3 (W ¼ 0.15) compared to our 1.5 (W ¼ 0.23). It must be noted that Cichon et al 8 used BPI as an affected phenotype, while we include BPII and SAM as affected in our narrow phenotypic model. Coding only BPI patients as affected in our sample results in a three-fold reduction in information followed by the same reduction in scores (LOD ¼ 1.12), without significant changes in localization.
One might find the great difference in LOD score in the parametric analysis compared to the original nonparametric analysis surprising. However, if the true mode of inheritance is dominant, the allele sharing assessed by nonparametric linkage is not expected to be as increased as in a recessive model. Additionally, information about the specific alleles that segregate in affected family members is underutilized by allele-sharing methods. This is particularly important with larger pedigrees and dominant diseases. The increased power of two-point parametric linkage is a subject that has long been argued in the literature. Marker positions are in centiMorgans from the Marshfield linkage maps (in parentheses when not actually present in the database). NPL scores, significance levels (GENEHUNTER), two-point LOD scores, and their corresponding recombination fractions are shown. Scores reaching suggestive levels according to Lander and Kruglyak 20 are in bold and the genomewide significant result is underlined.
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As opposed to the two-point, parametric multipoint analysis using the Cichon model failed to give a comparably high LOD score. Two-point analysis is much more robust to model misspecification, as it can account for phenocopies and heterogeneity by allowing for increased recombination. In multipoint analysis, however, model misspecification is more likely to produce lower LOD scores. 17 This is especially true for models with low phenocopy rates and disease alleles with low frequencies and high penetrance, because affected individuals not carrying the disease allele will be considered double recombinants and assigned extremely low likelihoods. The model of Cichon et al corresponds to a very high genotype relative risk, unlike what is suggested by the 'common diseasecommon variant' hypothesis. 18 When we used a model based on this hypothesis, with a frequent allele giving a moderate relative risk and being involved in about half of the disease cases in the population (phenocopies ¼ 1 2 of prevalence), we observed multipoint results comparable to the two-point results in our narrow phenotypic model. A slight decrease observed in the two-point results (accompanied however by lower thetas, see Table 2 ) probably suggests that our model is still not perfect and two-point analyses perform better when allowed to account for model misspecifications via recombination.
The lack of a positive association finding does not imply the absence of an associated haplotype. Although our high marker density prompted us perform the test for association, the marker spacing still far exceeds the average extent of linkage disequilibrium in the genome 26 and a negative finding was the most likely outcome. A study with a high density using the more abundant single nucleotide polymorphisms would be more likely to capture any existing disease-associated haplotypes.
Examination of the region in the Refseq database 27 showed 11 known genes within the 1-LOD interval.
We have identified three genes that are arguably The highest multipoint score was 2.49 between markers D8S529 and D8S256 (in bold) for the narrow phenotypic model. TG is involved in the production, sequestration, and release of thyroid hormones. Thyroid hormones are often useful adjuvants in the treatment of severe refractory BP disorder 28 and lithium, one of the most effective treatments for BP disorder, can alter thyroid function and TG structure. 29 Additionally, studies have reported increased antithyroid antibodies in BP disorder, [30] [31] [32] although results are inconsistent. [33] [34] [35] TG is one of the targets of such antibodies. Interestingly, TG, a gene with over 50 exons, has several coding polymorphisms, 10 of which result in aminoacid changes. 36 These are logical starting points for the investigation of this gene in BP disorder.
KCNQ3 codes for a voltage-gated potassium channel. KCNQ3 heteromers with other KCNQ family members are responsible for the M-current, which is involved in determining the excitability of neurons and their responsiveness to synaptic input. 37 Mutations in KCNQ3 cause epilepsy; 38 there is no known association with BP disorder. However, anticonvulsants are a common and successful treatment for BP disorder, and it is possible that subtle abnormalities and/or specific neuroanatomical variations of gene expression could be involved in the susceptibility to BP disorder.
Finally ADCY8, although located just outside our region, is a very interesting candidate. It codes for a brain adenyl-cyclase that catalyzes the formation of cyclic AMP (cAMP) from ATP. cAMP is a second messenger involved in the regulation of receptors, enzymes, ion channels, and gene transcription. There are multiple studies suggesting its involvement in BP disorder, both because of alterations in its levels and activity [39] [40] [41] [42] and because it is a target for lithium and other mood stabilizing agents. 43, 44 In summary, we present evidence that, taken together with independent findings by other investigators, strongly suggests the presence of a gene for BP disorder on chromosome 8q24. Furthermore, we make an argument for more appropriate models in multipoint linkage of complex disorders that consider the likelihood of the existence of common variants with low penetrance in these diseases. We also discuss three candidate genes, TG, KCNQ3, and ADCY8, that we believe deserve further attention. More work is needed in order to more precisely localize the linked locus and to examine the candidates, which reside in the region. We believe that these results are very promising, warranting intense investigation of 8q24, as there are now two independent investigative teams with evidence of genomewide significance for a susceptibility gene in this region.
